April 24 Biotech Update

Some news to talk about today with interesting implications and I will try to cover most of them. The sector seems to be lagging early despite some business development news.

April 22 Biotech Update

Another busy day so I have to keep this very short as I am trying to squeeze this in between meetings. In general, the sector seems to be doing fine.

April 21 Biotech Update

A lot of news to cover and I want to get to it all, so maybe a little less detail and more topics today and I will circle back to.

April 17 Biotech Update

The sector is certainly weak to start the day and obviously this seems driven by the macro. It was not immediately clear to me the trigger for the selling. Was.

Catalyst Watch – Vol. 3, Edition 5 (4/17/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

April 15 Biotech Update

It is a busy day so I am going to try and keep this short but every time I write that it seems like I write the same amount if.

Quick Note on GWPH

Embargoed Data was released yesterday in an announcement from AAN regarding GW Pharmaceuticals’ Epidiolex study: https://www.aan.com/PressRoom/Home/PressRelease/1364 This paragraph summarizes the Key Takeaway: “For the 137 people who completed the 12-week.

April 14 Biotech Update

A weak start to the day that essentially appears to be a continuation from the late selling yesterday. It still seems to be the case that large caps are underperforming.

April 13 Biotech Update

Happy merger Monday- well, happy Monday at least. The sector is off to a good start this week despite another dearth of deals this morning. It does worry me a.

April 10 Biotech Update

A good opening to the sector and large caps but the move was almost immediately faded (especially the large caps). Yesterday ended better than the past, so perhaps the sector.

CYNAF is OFF the Mark

Cynapsus is developing a sublingual film formulation of apomorphine for the treatment of acute “Off” episodes in patients with Parkinson’s Disease resulting from long term use of Levodopa. While Levodopa.

April 9th Biotech Update

The market is choppy this morning so it is difficult to read anything into the price action. I am growing slightly more constructive on the near term of the sector.

April 8 Biotech Update

It was actually a good morning for the sector with large and SMID caps doing well. While that is a good first step, we need these moves to not only.

April 6 Biotech Update

I have not had a chance to follow the market last week, so I do not really have a sense how the sector is doing. It looks like it has.

Catalyst Watch – Vol. 3, Edition 4 (4/3/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Chimera Research Group Catalyst Summary for March 2015

At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY).

BMY – Is the Technical Correction Done ?

  Bristol-Myers Squibb Company (BMY) –NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high.

March 31 Biotech Update

The sector was relatively weak yesterday and did not start this morning particular strong. I still am noticing the large cap lagging trend that has been going on for awhile..

March 30 Biotech Update

It looks like we have all survived the great biotech sell off of 2015. To be honest, I am not sure this really counts as a sell off (yet). We.

March 27 Biotech Update

The sector is in bounce mode. While I certainly think there is room for a rally after the sharp selling, I would not read this as an all clear. Yes,.

March 25 Biotech Update

A rough start to morning for the sector with a biotech bubble article in the WSJ not helping. There was nothing new but the headline is the headline (it also.

March 24 Biotech Update

Today seems to be a slow day, so I will try and keep it short and to the point. The sector held up better than I would have thought yesterday,.

March 23 Biotech Update

A weak start to the week but it is also a continuation from the weak ending of last week. Everyone is waiting for a pullback. The bulls expect a moderate.

March 20 Biotech Update

I believe there was some sort of data that came out today that had people talking. LOL. The BIIB data neatly dovetailed into biotech valuation discussion and so I want.

Catalyst Watch – Vol. 3, Edition 3 (3/18/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

March 18 Biotech Update

Some early weakness but I also suspect today is going to be fairly volatile with the Fed weighing in later this afternoon. So I am really not going to read.

March 17 Biotech Update

The market is weak but the biotech sector is showing good strength. The large caps seem to be holding up their end of the bargain, which bodes well for this.

Adamas Pharmaceuticals: two interesting programs for Alzheimer and Parkinsons Diseases

Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq   Adamas (ADMS) is a company focused on CNS diseases, specifically Parkinson’s (PD) and Alzheimer’s Diseases (AD). It has a low market cap (~$300M), plenty of.

Adamas Pharmaceuticals – Volatility Squeeze Action

  Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq   Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering.

March 16 Biotech Update

A good start to the week with a new all-time high in the IBB but I still want to see how the large caps perform in the afternoon. The pattern.

March 13 Biotech Update

I know that the sector is doing well and near highs but I cannot shake the feeling that the stocks feel heavy. I do not have a better way to.

Browsing 31 / 1 articles